Federal Register / Vol. 89, No. 198 / Friday, October 11, 2024 / Notices 82615 

Contact Person: Todd Everett White, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 594–3962, todd.white@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Medical Imaging. 

Date: November 7–8, 2024. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Krystyna H. Szymczyk, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 480–4198, szymczykk@

csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Cancer Diagnosis and Treatments 

(CDT). 

Date: November 7–8, 2024. 

Time: 9:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Victor A. Panchenko, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 802B2, 

Bethesda, MD 20892, (301) 867–5309, 

victor.panchenko@nih.gov. 

Name of Committee: Genes, Genomes, and 

Genetics Integrated Review Group; Genetic 

Variation and Evolution Study Section. 

Date: November 7–8, 2024. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: The Bethesdan Hotel, 8120 

Wisconsin Avenue, Bethesda, MD 20814. 

Meeting Format: In Person. 

Contact Person: Michael Patrick O’Connell, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 867–5309, oconnellmp@

mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Fellowships: Cell Biology, Developmental 

Biology, and Bioengineering. 

Date: November 7, 2024. 

Time: 9:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Mark Caprara, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5156, 

MSC 7844, Bethesda, MD 20892, 301–613– 

5228, capraramg@mail.nih.gov. 

Name of Committee: Integrative, 

Functional and Cognitive Neuroscience 

Integrated Review Group; Neurobiology of 

Motivated Behavior Study Section. 

Date: November 7–8, 2024. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Janita N. Turchi, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 402–4005, turchij@mail.nih.gov. 

Name of Committee: Molecular, Cellular 

and Developmental Neuroscience Integrated 

Review Group; Neural Oxidative Metabolism 

and Death Study Section. 

Date: November 7–8, 2024. 

Time: 9:30 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Christine Jean DiDonato, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 1014J, 

Bethesda, MD 20892, (301) 435–1042, 

didonatocj@csr.nih.gov. 

Name of Committee: Aging and 

Neurodegeneration Integrated Review Group; 

Cellular and Molecular Biology of 

Neurodegeneration Study Section. 

Date: November 7–8, 2024. 

Time: 9:30 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Meeting Format: In Person and Virtual 

Meeting. 

Contact Person: Laurent Taupenot, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4188, 

MSC 7850, Bethesda, MD 20892, 301–435– 

1203, laurent.taupenot@nih.gov. 

Name of Committee: Infectious Diseases 

and Immunology A Integrated Review Group; 

Innate Immunity B Study Section. 

Date: November 7–8, 2024. 

Time: 9:30 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Meeting Format: In Person and Virtual 

Meeting. 

Contact Person: Bakary Drammeh, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 805–P, 

Bethesda, MD 20892, (301) 435–0000, 

drammehbs@csr.nih.gov. 

Name of Committee: Population Sciences 

and Epidemiology Integrated Review Group; 

Aging, Injury, Musculoskeletal, and 

Rheumatologic Disorders Study Section. 

Date: November 7–8, 2024. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Nketi I. Forbang, MD, 

MPH, Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 1006K1, 

Bethesda, MD 20892, (301) 594–0357, 

forbangni@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: October 7, 2024. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–23542 Filed 10–10–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Arthritis and 

Musculoskeletal and Skin Diseases; 

Notice of Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Arthritis and Musculoskeletal and Skin 

Diseases Special Emphasis Panel; NIAMS 

Ancillary 2025/01 Review Meeting. 

Date: November 12, 2024. 

Time: 10:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, One 

Democracy Plaza, 6701 Democracy 

Boulevard, Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Chiguang Feng, Ph.D., 

Scientific Review Officer, Scientific Review 

Officer, Scientific Review Branch, Extramural 

Program, Arthritis and Musculoskeletal and 

Skin Diseases, 6701 Democracy Boulevard, 

Bethesda, MD 30892, (301) 451–7766, 

chiguang.feng@nih.gov. 


ddrumheller on DSK120RN23PROD with NOTICES1
82616 Federal Register / Vol. 89, No. 198 / Friday, October 11, 2024 / Notices 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.846, Arthritis, 

Musculoskeletal and Skin Diseases Research, 

National Institutes of Health, HHS) 

Dated: October 8, 2024. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–23632 Filed 10–10–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Novel Approaches for 

Radiation Biodosimetry Assays and Devices 

Development (U01 Clinical Trial Not 

Allowed). 

Date: November 12–13, 2024. 

Time: 9:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3G22, 

Rockville, MD 20892 (Video Assisted 

Meeting). 

Contact Person: Michael M. Opata, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 5601 

Fishers Lane, Room 3G22, Rockville, MD 

20892, 240–627–3319, michael.opata@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: October 7, 2024. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–23543 Filed 10–10–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Aging; Amended 

Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the Board of Scientific 

Counselors, NIA, October 22, 2024, 8 

a.m. to October 24, 2024, 11:30 a.m., 

National Institutes of Health, 

Biomedical Research Center, 251 

Bayview Boulevard, Baltimore, MD, 

21224 which was published in the 

Federal Register on July 9, 2024, 89 FR 

56395. 

The following FRN is being amended 

to change the meeting times from 8 

a.m.–2 p.m. to 8 a.m.–4:30 p.m. on 

October 22, 2024; from 8 a.m.–6 p.m. to 

8 a.m.–5 p.m. on October 23, 2024; from 

8 a.m.–11:30 a.m. to 8 a.m.–1:30 p.m. on 

October 24, 2024. The meeting is 

partially closed to the public. 

Dated: October 8, 2024. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–23636 Filed 10–10–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Agency Information Collection 

Activities: Comment Request 

In compliance with section 

3506(c)(2)(A) of the Paperwork 

Reduction Act of 1995 concerning 

opportunity for public comment on 

proposed collections of information, the 

Substance Abuse and Mental Health 

Services Administration (SAMHSA) 

will publish periodic summaries of 

proposed projects. To request more 

information on the proposed projects or 

to obtain a copy of the information 

collection plans, call the SAMHSA 

Reports Clearance Officer at (240) 276– 

0361. 

Comments are invited on: (a) whether 

the proposed collections of information 

are necessary for the proper 

performance of the functions of the 

agency, including whether the 

information shall have practical utility; 

(b) the accuracy of the agency’s estimate 

of the burden of the proposed collection 

of information; (c) ways to enhance the 

quality, utility, and clarity of the 

information to be collected; and (d) 

ways to minimize the burden of the 

collection of information on 

respondents, including through the use 

of automated collection techniques or 

other forms of information technology. 

Proposed Project: Treatment Episode 

Data Set (TEDS) (OMB No. 0930– 

0335)—Revision 

The Center for Behavioral Health 

Statistics and Quality (CBHSQ) at the 

Substance Abuse and Mental Health 

Services Administration (SAMHSA) is 

requesting an extension with changes to 

the combined data collection of the 

Treatment Episode Data Set (TEDS), the 

Mental Health Client Level Data (MH– 

CLD), and the Mental Health Treatment 

Episode Data Set (MH–TEDS) (OMB No. 

0930–0335), which expires on December 

31, 2024. 

TEDS collects episode-level data on 

clients aged 12 and older receiving 

substance use treatment services from 

publicly funded facilities. MH–CLD 

collects demographic, clinical, and 

National Outcome Measures data on 

clients receiving mental health and 

support services funded or operated by 

the State Mental Health Agencies 

(SMHAs). MH–TEDS is an alternative 

reporting method to MH–CLD. It 

collects episode-level data on clients 

receiving mental health treatment 

services from publicly funded facilities. 

MH–TEDS data can be converted to 

MH–CLD format. 

Under section 505 of the Public 

Health Service Act (42 U.S.C. 290aa–4), 

CBHSQ is authorized to collect annual 

data on the national incidence and 

prevalence of the various forms of 

mental illness and substance abuse. 

CBHSQ is also authorized to collect data 

on the number and variety of public and 

nonprofit private mental health and 

substance use treatment programs and 

the number and demographic 

characteristics of individuals receiving 

treatment through such programs. In 

addition, States, receiving fundings 

from SAMHSA’s Community Mental 

Health Services Block Grant (MHBG) 

and Substance Use Prevention, 

Treatment, and Recovery Services Block 

Grant (SUPTRS BG) (formally known as 

the Substance Abuse Prevention and 

Treatment Block Grant (SABG), utilize 

TEDS and MH–CLD/MH–TEDS data to 

meet the block grant reporting mandate 

and requirement. 

SAMHSA is requesting OMB approval 

of revisions to the TEDS/MH–CLD/MH– 


ddrumheller on DSK120RN23PROD with NOTICES1